



(43) International Publication Date
2 May 2013 (02.05.2013)

(10) International Publication Number
WO 2013/060770 A1

(51) International Patent Classification:

A61K 38/38 (2006.01) A61K 47/42 (2006.01)
A61K 38/48 (2006.01) A61L 24/10 (2006.01)

(21) International Application Number:

PCT/EP2012/071136

(22) International Filing Date:

25 October 2012 (25.10.2012)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

61/552,270 27 October 2011 (27.10.2011) US

(71) Applicants: **BAXTER INTERNATIONAL INC.**
[US/US]; One Baxter Parkway, Deerfield, Illinois 60015
(US). **BAXTER HEALTHCARE S.A.** [CH/CH]; Thur-
gauerstrasse 130, CH-8152 Glattpark (Opfikon) (CH).

(72) Inventors: **MCCOY, Jill**; 1380 Thunderbird Avenue,
Sunnyvale, CA 94087 (US). **DWYER, Joseph F.**; 1371
Oxford Lane, Apt. 106, Round Lake, IL 60073 (US).
YANG, Ziping; 2111 Jordan Terrace, Buffalo Grove, IL
60089 (US).

(74) Agent: **SONN & PARTNER PATENTANWÄLTE**;
Riemergasse 14, A-1010 Vienna (AT).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY,

BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IS, JP, KE, KG, KM, KN, KP,
KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD,
ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI,
NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU,
RW, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ,
TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA,
ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, GH,
GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ,
UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV,
MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM,
TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a
patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the
earlier application (Rule 4.17(iii))
- of inventorship (Rule 4.17(iv))

Published:

- with international search report (Art. 21(3))

(54) Title: HEMOSTATIC COMPOSITIONS

(57) Abstract: The invention discloses a hemostatic composition comprising crosslinked gelatin in particulate form suitable for use in hemostasis, wherein the composition is present in paste form containing 15.0 to 19.5% (w/w), preferably 16.0 to 19.5% (w/w), 16.5 to 19.5% (w/w), 7.0 to 18.5% (w/w) or 17.5 to 18.5% (w/w), more preferred 16.5 to 19.0% (w/w) or 16.8 to 7.8% (w/w), especially preferred 16.5 to 17.5% (w/w), and wherein the composition comprises an extrusion enhancer.



WO 2013/060770 A1